Health & Fitness
Thu, July 16, 2009Wed, July 15, 2009Tue, July 14, 2009Mon, July 13, 2009Fri, July 10, 2009Thu, July 9, 2009Wed, July 8, 2009Tue, July 7, 2009Mon, July 6, 2009Fri, July 3, 2009Thu, July 2, 2009Wed, July 1, 2009Tue, June 30, 2009Mon, June 29, 2009Fri, June 26, 2009Thu, June 25, 2009Wed, June 24, 2009Tue, June 23, 2009Mon, June 22, 2009Sun, June 21, 2009Fri, June 19, 2009Thu, June 18, 2009Wed, June 17, 2009Tue, June 16, 2009Mon, June 15, 2009Fri, June 12, 2009Thu, June 11, 2009Wed, June 10, 2009Tue, June 9, 2009Mon, June 8, 2009Sun, June 7, 2009Fri, June 5, 2009Thu, June 4, 2009Wed, June 3, 2009Tue, June 2, 2009Mon, June 1, 2009Sat, May 30, 2009Fri, May 29, 2009Thu, May 28, 2009Wed, May 27, 2009Tue, May 26, 2009Mon, May 25, 2009Fri, May 22, 2009Thu, May 21, 2009Wed, May 20, 2009Tue, May 19, 2009Mon, May 18, 2009Fri, May 15, 2009Thu, May 14, 2009Wed, May 13, 2009Tue, May 12, 2009Mon, May 11, 2009Fri, May 8, 2009Thu, May 7, 2009Thu, April 16, 2009Wed, April 15, 2009Tue, April 14, 2009CTD Holdings, Inc.: CTD Holdings to Institutionalize Niemann-Pick C Efforts
Published in Health and Fitness on Monday, June 8th 2009 at 5:15 GMT, Last Modified on 2009-06-08 05:16:54 by Market Wire
HIGH SPRINGS, FL--(Marketwire - June 8, 2009) - CTD Holdings, Inc. ( CTDH is currently applying for Trademark protection for Cyclo™, a new product line to be used exclusively for research and compassionate use in conjunction with dysfunctional cholesterol metabolism ailments and diseases. Currently, the product is being used under an FDA approved compassionate use treatment for Niemann-Pick C patients. "The Addi and Cassi Hempel (see [ www.WebofHope.com ]) compassionate use trial with Cyclo™ has initiated worldwide contacts from physicians treating Niemann-Pick C patients in the US, India, Lebanon, Spain, Japan, and China. Additionally, the medical research community in the US and England, specializing in cholesterol metabolism, are ordering Trappsol® (CTD's branded CDs) radiolabelled Cyclo™," stated Mr. C.E. Strattan (Pres/CEO). "It appears that Cyclo™'s role in dysfunctional cholesterol metabolism has come to the attention of some very qualified medical research faculties." Dysfunctional cholesterol metabolism has been implicated in the etiology of Adult and Childhood Alzheimer's, HIV Aids, Coronary Artery Disease, and Diabetes. "Creating the conduit for the efficient collection of the compassionate use data will expedite routine use of Cyclo™ in ameliorative scenarios," promises Mr. Strattan. About CTD Holdings, Inc. The company is the one-stop shop, business to business facilitator of commercial and research applications of cyclodextrins. With its branded Trappsol® and Aquaplex® product offerings, CTDH scientists coordinate the development of commercial products for use in the pharmaceuticals, foods, hazardous waste treatment, and cosmetics industries, just to name a few of the industries which endeavor to put non water-soluble ingredients into water-based formulations. More recently CTDH has worked, in an advisory capacity, on the benefits and application of Cyclodextrins as a treatment for Niemann Picks disease, a debilitating childhood disease often associated with Alzheimer's. CTDH was founded in 1990 as a Florida corporation and became a public company in 1994. Additional information on the Company can be found on the Company's website: [ www.cyclodex.com ] This news release contains "forward-looking statements" that are made pursuant to the safe harbor provisions of the Private Securities Litigation Reform Act of 1995. You are cautioned that such statements are subject to risks and uncertainties that could cause future circumstances, events or results to differ materially from those projected in the forward-looking statements. CTDH complies with the regulations and time lines mandated by the SEC in the filing of its financial reports; these filings also contain forward-looking statements. The above forward-looking statements are made as of the date above; CTD Holdings, Inc accepts no specific responsibility for updating such statements.
